It is worth saying clearly: GHK-Cu in compounded formulations is not FDA-approved for any specific indication
IRF1 drives the expression of the transferrin receptor, promotes intracellular Fe2+ accumulation, disrupts iron homeostasis, and induces ferroptosis in cancer cells, while blocking Gln enhances this effect (92)
Glutathione l phn t protein nh c hnh thnh t cc axit amin cysteine, glycine, axit glutamic
However, just like our original liposomal glutathione, this S-Acetyl-glutathione is bound to a fatty phospholipid complex for optimal absorption and protection of glutathione
The sub-30-minute plasma half-life is the pharmacokinetic basis for twice-daily dosing, though no human study has confirmed this produces better outcomes
If your vendor label says "CJC-1295" without specifying DAC, assume it is the no-DAC version (Mod GRF 1-29) unless confirmed otherwise